Cooley Strengthens Global Capital Markets Practice and Healthcare & Life Sciences Platform

Shanghai – March 30, 2021 – Acclaimed corporate lawyer Yiming Liu has joined Cooley as a partner in the firm’s global capital markets practice. Based in Shanghai, Liu bolsters Cooley’s healthcare & life sciences platform and its capital markets, M&A, and partnering and licensing capabilities across the Asia Pacific region. He arrives from O’Melveny & Myers.

“Yiming’s broad deal experience, technical skills and deep background in science add immense value to our platform,” said Dave Peinsipp, co-head of Cooley’s global capital markets practice alongside Charlie Kim. “Along with his exceptional capabilities in cross-border M&A and technology transactions, he is one of the most experienced and sought-after life sciences IPO lawyers in Asia, with an established reputation among leading healthcare founders, bankers and investors alike. We are thrilled to bring him on board.”

“We are extremely enthusiastic about Yiming’s arrival,” added Kim. “At Cooley, we view our practices in Asia, Europe and the US as one. In a world where racial and nationalistic divides fill the headlines, we embrace the vision of operating as a truly diverse and unified cross-border team – and Yiming shares that vision. His many specialties and team-based approach enhance and complement our team’s skills and cultural ethos.”

Liu specializes in capital markets, M&A and technology transactions in the life sciences and high-tech industries. Leveraging his technical background, he has advised on numerous high-profile life sciences IPOs in recent years. In addition, on behalf of clients in the US, Europe and China, Liu has successfully led the negotiation and documentation of a wide range of cross-border transactions, including M&A, private financings, joint ventures, and partnering and licensing arrangements.

“I’ve been incredibly impressed with Cooley as it continues to build on its exceptional capital markets and life sciences practices in Asia, Europe and the US,” Liu said. “The firm’s aspirations in the region, particularly in the healthcare industry, complement the goals for my own practice perfectly. I am excited to collaborate with partners of the caliber of Will Cai, Michael Yu and Christina Zhang, along with the entire global team of leading practitioners.”

Before earning his JD from Columbia University, Liu received master’s degrees in molecular, cellular and developmental biology and health services administration from the University of Michigan, as well as a BS in biological sciences from Fudan University in Shanghai. He is admitted to practice in New York.

Cooley is one of the world’s top firms working on global capital markets transactions for non-US issuers. The firm represents some of Asia’s most innovative and dynamic technology and life sciences companies, advising on financing, joint venture and other strategic transactions. Cooley has been the #1 law firm advising companies going public across all industries since 2014, the #1 law firm for venture-backed IPOs across all industries for 15+ years, and the #1 law firm representing companies as well as investment banks on IPOs in the life sciences sector in 2020, according to IPO Vital Signs and PitchBook. In 2020, the firm earned its third Capital Markets Practice Group of the Year award from Law360 and was named one of the decade’s top IPO legal advisers by Bloomberg Law.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 1,100+ lawyers across 16 offices in the United States, Asia and Europe.

Related Contacts
Yiming Liu Partner, Shanghai